Regeneron Pharmaceuticals, Inc.

Company: Regeneron Pharmaceuticals, Inc.

Deadline: TBD

Kaskela Law LLC is investigating Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) on behalf of the Company’s stockholders.

On June 24, 2020, the U.S. Attorney’s Office filed a complaint against Regeneron for alleged violations of the False Claims Act.  The complaint alleges that the Company engaged in a sophisticated kickback scheme through which it funneled tens of millions of dollars from a foundation with the goal of covering the co-pay costs of Medicare patients utilizing the Company’s Eylea drug.  According to the complaint, this scheme undermined the medical system and wasted taxpayers’ monies by causing Medicare to pay out nearly $2 billion for access to the drug.  Further according to the complaint, “[b]ecause the anti-kickback statute, 42 U.S.C. § 1320-7b(b), prohibits such “indirect” kickbacks to subsidize the price of a drug reimbursed by Medicare, Regeneron’s conduct was illegal, and senior management knew it.”

The investigation seeks to determine whether the members of Regeneron’s board of directors breached their fiduciary duties to the Company and its stockholders in connection with the above, including by failing to implement and maintain an effective system of internal controls over operations.

Current Regeneron stockholders who purchased or acquired shares of the Company’s stock prior to January 1, 2016 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 – 1585, or by completing the information form on this page, to discuss this investigation and their legal rights and options.

Submit Your Information

  • Date Format: MM slash DD slash YYYY
  • This field is for validation purposes and should be left unchanged.